FDA Approves Tremfya for Ulcerative Colitis

MONDAY, Sept. 16, 2024-- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.Tremfya is the first and only dual-acting interleukin-23 inhibitor...